NRIX Nurix Therapeutics

Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20 at 3:00 p.m. ET.

The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under . The archived webcast will be available on the Nurix website for 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit .

Contacts:

Investors

Silinda Neou

Nurix Therapeutics

Elizabeth Wolffe, Ph.D.

Wheelhouse Life Science Advisors

Media

Aljanae Reynolds

Wheelhouse Life Science Advisors

 



EN
11/04/2023

Underlying

NRIXNurix Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nurix Therapeutics

 PRESS RELEASE
Free
NRIX Nurix Therapeut...

Nurix Therapeutics Announces $250.0 Million Registered Offering of Com...

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the pricing of its underwritten registered offering of 24,485,799 shares of its common stock at a price of $10.21 per share. The gross proceeds to Nurix from the offering, before deducting underwriting discounts and commissions ...

October 22, 2025 1 EN
 PRESS RELEASE
Free
NRIX Nurix Therapeut...

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or...

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor webcast today, Wednesday, October 22nd, at 8:00 a.m. EDT SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ...

October 22, 2025 1 EN
 PRESS RELEASE
Free
NRIX Nurix Therapeut...

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral ...

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 demonstrated evidence of monotherapy anti-tumor activity with reductions in tumor biomarkers, tumor shrinkage, long-term stable disease, and a confirmed partial response in heavily...

October 18, 2025 1 EN
 PRESS RELEASE
Free
NRIX Nurix Therapeut...

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Pr...

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4 degrader in collaboration with Gilead, showing potent pathway inhibition and efficacy in a dermatitis model Well capitalized with cash and marketable securities of $428.8 million SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-sta...

October 9, 2025 1 EN
 PRESS RELEASE
Free
NRIX Nurix Therapeut...

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader...

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers is ongoing Data are being presented at the European Academy of Dermatology and Venereology (EADV) Congress SAN FRANCISCO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the presentation of preclinical data from GS-6791/NX-...

September 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch